Collectively, these results indicated that PTEN-deficient CRC cells harbored a low basal level of p53 due to the activated AKT-MDM2 axis, while a remarkable activation of p53 in PTEN-deficient CRC cells upon MDM2 inhibition could trigger the selective antitumor effect in the cells. The gene discussed is TP53; the disease is colorectal carcinoma.